ValueQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMSelling/general/admin expenses5.47 M5.89 M8.88 M8.44 M12.8 M36.01 MResearch & development18.9 M21.48 M33.69 M28.61 M32.89 M116.68 M영업 이익-23.86 M-26.62 M-41.11 M-34.28 M-45.05 M-147.06 MNon-Operating Income, Total——————Interest expense, net of interest capitalized——————Non-Operating Income, excl. Interest Expenses——————Unusual income/expense——————Pretax income-23.01 M-27.08 M-41.76 M-33.16 M-44.45 M-146.46 MEquity in earnings——————Taxes7 0000117 K0374 K491 KNon-controlling/minority interest——————After tax other income/expense672 K-465 K-537 K-12 K1.23 M219 KNet income before discontinued operations-23.02 M-27.08 M-41.88 M-33.16 M-44.83 M-146.95 MDiscontinued operations——————Net income-23.02 M-27.08 M-41.88 M-33.16 M-44.83 M-146.95 MDilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders-23.02 M-27.08 M-41.88 M-33.16 M-44.83 M-146.95 MBasic earnings per share (Basic EPS)-0.23-0.26-0.31-0.24-0.24-1.05Diluted earnings per share (Diluted EPS)-0.23-0.26-0.31-0.24-0.24-1.05Average basic shares outstanding97 M102.62 M134.48 M136.81 M139.57 M513.48 MDiluted shares outstanding97 M102.62 M134.48 M136.81 M139.57 M513.48 MEBITDA——————EBIT-23.86 M-30.9 M-47.08 M-37.96 M-47.18 M-163.12 MCost of revenue—4.29 M5.96 M3.68 M2.13 M16.06 MOther cost of goods sold—4.29 M5.96 M3.68 M2.13 M16.06 MDepreciation & amortization (cash flow)——————
DBV Technologies S.A. - American Depositary Shares
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.